Leukemia, Myeloid, Acute: all 3,035 studies

Page 27 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.

• Drug Biomarkers in Cell Samples From Patients With Acute Myeloid LeukemiaCompletedNCT01150058
• Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced LeukemiasCompletedNCT01149915Phase 1
• Decitabine Maintenance in Elderly Acute Myeloid Leukemia PatientsCompletedNCT01149408Phase 1
• Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)CompletedNCT01147939Phase 3
• Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)Status unknownNCT01146977Phase 2
• Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)Status unknownNCT01146262Phase 1/2
• Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic LeukemiaCompletedNCT01146223
• Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01146210
• Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)Status unknownNCT01145846Phase 3
• Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid LeukemiaStatus unknownNCT01141673
• Veliparib and Temozolomide in Treating Patients With Acute LeukemiaCompletedNCT01139970Phase 1
• Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01132586Phase 1
• Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid LeukemiaCompletedNCT01130662Phase 1
• Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01130506Phase 1
• Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01127009Phase 1
• A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid LeukemiaCompletedNCT01126814Phase 1/2
• First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell CancersCompletedNCT01120457Phase 1
• Prevention of Left Ventricular Dysfunction During ChemotherapyCompletedNCT01110824Phase 3
• ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic MalignanciesCompletedNCT01110473Phase 1
• Genetic Predictive Model Based on Single Nucleotide Polymorphisms in the DNA Repair Pathway and Drug Metabolis/Transport Pharmacogenetics in the Prediction of Response and Treatment Outcomes in Acute Myeloid LeukemiaStatus unknownNCT01106144
• A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)CompletedNCT01090167Phase 1
• A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDSTerminatedNCT01085656Phase 1
• Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid LeukemiaCompletedNCT01076569
• A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell TransplantationCompletedNCT01068301Phase 1
• ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)WithdrawnNCT01067274Phase 3
• A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)Status unknownNCT01066494Phase 2
• Genome-wide Pharmacogenetic Candidate Gene Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal KaryotypeStatus unknownNCT01066338
• Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid LeukemiaStatus unknownNCT01066286
• The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid LeukemiaWithdrawnNCT01065545Phase 1
• Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)CompletedNCT01063660Phase 2
• S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid LeukemiaCompletedNCT01059734
• Studying Biomarkers in Cell Samples From Patients With Acute Myeloid LeukemiaCompletedNCT01057199
• Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid MalignanciesCompletedNCT01056614Phase 2
• A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT01055483Phase 1
• Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
• Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid LeukemiaCompletedNCT01050036Not applicable
• Targeted, Dose-Escalation Busulfan-Etoposide as Prep RegimenCompletedNCT01048827Phase 1
• MSC and HSC Coinfusion in Mismatched MinitransplantsTerminatedNCT01045382Phase 2
• 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT01041443Phase 1
• LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)CompletedNCT01041040Phase 4
• Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid LeukemiaStatus unknownNCT01039363Phase 2
• PR104 in Treating Patients With Refractory/Relapsed Acute LeukemiaStatus unknownNCT01037556Phase 1/2
• A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid LeukaemiaCompletedNCT01035502Phase 2
• High-dose Cytarabine and Survival in AMLCompletedNCT01034839
• A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT01034410Phase 2
• Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01031368Phase 1
• IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)TerminatedNCT01027923Phase 1
• Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid LeukemiaCompletedNCT01024127
• Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk LeukemiaCompletedNCT01020539Phase 1
• An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)CompletedNCT01019161Phase 1
• Unrelated Double Umbilical Cord Blood Units TransplantationStatus unknownNCT01015742Phase 2/3
• Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell TransplantationCompletedNCT01015196Phase 2/3
• Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) PatientsSuspendedNCT01010373Phase 2
• Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid LeukemiaCompletedNCT01005277
• Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720CompletedNCT01004965
• Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)CompletedNCT01001143Phase 1
• Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose CytarabineCompletedNCT00995332Phase 1/2
• Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic MalignancyCompletedNCT00990587Phase 1
• Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00990054Phase 1
• Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeCompletedNCT00988715Phase 1
• Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post TransplantCompletedNCT00986804Phase 1
• Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic SyndromesCompletedNCT00981240Phase 1
• Study of Dosage Individualisation for the Treatment of Acute Myeloid LeukemiaCompletedNCT00969891
• Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction CourseWithdrawnNCT00967512Phase 2
• Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and MyelomaCompletedNCT00965224Phase 2
• A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous LeukemiaCompletedNCT00964873Phase 1
• Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological MalignancyTerminatedNCT00963495Phase 1
• Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular RemissionCompletedNCT00962767Phase 3
• Maintenance Therapy in Acute Myeloid Leukemia (AML) PatientsCompletedNCT00957385Phase 2
• Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 MutationsCompletedNCT00943943Phase 1
• A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) SubjectsWithdrawnNCT00943553Phase 2
• 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
• The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)CompletedNCT00932412Phase 2
• Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2CompletedNCT00931138Phase 3
• A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years OldCompletedNCT00927498Phase 3
• Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)CompletedNCT00926731Phase 1
• GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the ElderlyCompletedNCT00925873Phase 3
• Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic SyndromesTerminatedNCT00923234Phase 1
• Pilot Study of Unrelated Cord Blood TransplantationTerminatedNCT00916045Phase 2
• Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and ThymoglobulinTerminatedNCT00915811Phase 2
• Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic AbnormalitiesCompletedNCT00915785Phase 2
• Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT00915252Phase 2
• MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic LeukemiaCompletedNCT00911066Phase 1
• Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)CompletedNCT00909168Phase 2/3
• Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic MalignanciesCompletedNCT00908167Phase 1
• Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)CompletedNCT00903422Phase 1
• QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00900809Phase 1
• Studying Tissue and Blood Samples From Patients With Acute Myeloid LeukemiaActive, not recruitingNCT00900224
• Studying Fentanyl in Patients With CancerTerminatedNCT00899951
• Multidrug Resistance Genes in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT00898456
• Genetics Study of Tissue Collected From Patients With Acute Myeloid LeukemiaStatus unknownNCT00898092
• Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2CompletedNCT00896701
• Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene MutationCompletedNCT00893399Phase 3
• Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of AgeCompletedNCT00893373Phase 2
• Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic SyndromeCompletedNCT00892190Phase 1
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
• Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AMLStatus unknownNCT00887042Phase 1/2
• A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5qStatus unknownNCT00885508Phase 2
• Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)CompletedNCT00880243Phase 3
• Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)CompletedNCT00875745Phase 1

← Leukemia, Myeloid, Acute overview